These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 38263810

  • 1. Cost-effectiveness analysis of mecapegfilgrastim and recombinant human granulocyte stimulating factor for primary prophylaxis of chemotherapy-induced neutropenia in non-small cell lung cancer.
    Gu YL, Sun ZX, Sun Y, Guan X, Jiang DL.
    Int J Clin Pharmacol Ther; 2024 Mar; 62(3):115-121. PubMed ID: 38263810
    [Abstract] [Full Text] [Related]

  • 2. A Randomized Multicenter Phase III Study of Single Administration of Mecapegfilgrastim (HHPG-19K), a Pegfilgrastim Biosimilar, for Prophylaxis of Chemotherapy-Induced Neutropenia in Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC).
    Zhou C, Huang Y, Wang D, An C, Zhou F, Li Y, Chen G, Wu C, He J, Wu G, Song X, Gao J, Liu W, Li B, Shi J, Huang C, Yu J, Feng J, Yue H, Shi M, Xia J.
    Clin Lung Cancer; 2016 Mar; 17(2):119-27. PubMed ID: 26781346
    [Abstract] [Full Text] [Related]

  • 3. Clinical efficacy and safety of mecapegfilgrastim in small cell lung cancer as primary prophylaxis of neutropenia post chemotherapy: a retrospective analysis.
    Gu X, Zhang Y.
    Ann Palliat Med; 2021 Jul; 10(7):7841-7846. PubMed ID: 34353071
    [Abstract] [Full Text] [Related]

  • 4. Mecapegfilgrastim in Chemotherapy-Induced Neutropenia: A Profile of Its Use in China.
    Al-Salama ZT, Keam SJ.
    Clin Drug Investig; 2019 Oct; 39(10):1009-1018. PubMed ID: 31489570
    [Abstract] [Full Text] [Related]

  • 5. [A multicenter, randomized, controlled, phase Ⅲ clinical study of PEG-rhG-CSF for preventing chemotherapy-induced neutropenia in patients with breast cancer and non-small cell lung cancer].
    Xu B, Tian F, Yu J, Song Y, Shi J, Zhang B, Zhang Y, Yuan Z, Wu Q, Zhang Q, Nan K, Sun Q, Li W, Hu J, Bi J, Meng C, Dai H, Jiang H, Yue S, Cao B, Sun Y, Wang S, Tong Z, Shen P, Wu G, Tang L, Deng Y, Jia L, Shen K, Zhuang W, Xie X, Wu Y, Chen L.
    Zhonghua Zhong Liu Za Zhi; 2016 Jan; 38(1):23-7. PubMed ID: 26796802
    [Abstract] [Full Text] [Related]

  • 6. [Treatment of chemotherapy-induced neutropenia pegylated recombinant human granulocyte colony-stimulating factor: a multi-center randomized controlled phase II clinical study].
    Shi YK, He XH, Yang S, Wang HQ, Jiang ZF, Zhu YZ, Ke XY, Zhang Y, Liu YP, Zhang WJ, Wang Z, Shi QZ, Xie XD, Zhang HL, Wang JJ, Luo DY, Zheng QS, Sun RY.
    Zhonghua Yi Xue Za Zhi; 2006 Dec 26; 86(48):3414-9. PubMed ID: 17313855
    [Abstract] [Full Text] [Related]

  • 7. Prophylactic administration of mecapegfilgrastim after chemotherapy in patients with lymphoma.
    Zheng M, Wen X, Su L.
    Ann Palliat Med; 2021 Dec 26; 10(12):12055-12060. PubMed ID: 35016412
    [Abstract] [Full Text] [Related]

  • 8. [Phase I clinical trail of intravenous pegylated recombinant human granulocyte colony-stimulating factor].
    Shi YK, Liu P, Yang S, Han XH, He XH, Ai B, Qin Y, Li B, Huang DZ, Zhang CG, Sun Y.
    Ai Zheng; 2006 Apr 26; 25(4):495-500. PubMed ID: 16613688
    [Abstract] [Full Text] [Related]

  • 9. PEG-rhG-CSF for prophylaxis of neutropenia after chemotherapy in patients with non-small cell lung cancer: A multicenter, prospective, randomized study.
    Sun XS, Wang Z, Ren SH, Zhang HL, Liu LJ, Du HB, Liu XW, Liu JF.
    Thorac Cancer; 2022 Sep 26; 13(17):2429-2435. PubMed ID: 35859328
    [Abstract] [Full Text] [Related]

  • 10. Optimal schedule for administering granulocyte colony-stimulating factor in chemotherapy-induced neutropenia in non-small-cell lung cancer.
    Soda H, Oka M, Fukuda M, Kinoshita A, Sakamoto A, Araki J, Fujino S, Itoh N, Watanabe K, Kanda T, Nakano M, Hara K.
    Cancer Chemother Pharmacol; 1996 Sep 26; 38(1):9-12. PubMed ID: 8603458
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of 3 mg pegylated recombinant human granulocyte colony-stimulating factor as support to chemotherapy for lung cancer.
    Ji X, Xu L, Pan P, Xu Z, Wang A, Li Y.
    Thorac Cancer; 2022 Jan 26; 13(1):117-125. PubMed ID: 34791805
    [Abstract] [Full Text] [Related]

  • 12. [Efficacy of once-per-cycle administration pegylated recombinant human granulocyte colony-stimulating factor in chemotherapy-induced neutropenia in a phase I trial].
    Yang S, Shi YK, Liu P, Han XH, He XH, Cai YM, Chen ZM.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Jun 26; 28(3):339-44. PubMed ID: 16900629
    [Abstract] [Full Text] [Related]

  • 13. [Clinical study of recombinant human granulocyte colony-stimulating factor (RHG-CSF) on leucopenia induced by chemotherapy with CE regimen on lung cancer patients].
    Shi YK, Feng FY, Sun Y.
    Zhonghua Nei Ke Za Zhi; 1994 Nov 26; 33(11):739-42. PubMed ID: 7541325
    [Abstract] [Full Text] [Related]

  • 14. [Cost-effectiveness of primary prophylaxis with PEG-rhG-CSF in early-stage breast cancer patients receiving chemotherapy in China].
    Xia W, Wang SS, Hu H, Zhao FL, Xu F, Hong RX, Jiang KK, Yuan ZY, Shi YX, Zhao K, Huang JJ, Xue C, Bi XW, Lu QY, An X, Zhang JM.
    Zhonghua Zhong Liu Za Zhi; 2020 Oct 23; 42(10):861-867. PubMed ID: 33113628
    [Abstract] [Full Text] [Related]

  • 15. A prospective, randomized clinical trial of emergency treatment of chemotherapy-induced neutropenia and febrile neutropenia by pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF).
    Huang X, Li S, Shi W, Wang Y, Wan X, He J, Xu Y, Zhang W, Shi X, Chen R, Xu L, Zha X, Wang J.
    Br J Clin Pharmacol; 2023 Jan 23; 89(1):372-379. PubMed ID: 36001055
    [Abstract] [Full Text] [Related]

  • 16. Outcome and Cost-Effectiveness Analysis of Long-acting G-CSF as Primary Prophylaxis of Neutropenia Induced by Chemotherapy in Breast Cancer Patients, From a Retrospective Study.
    Wang Y, Zhao C, Ma P, Jiang D.
    Cancer Control; 2023 Jan 23; 30():10732748221140289. PubMed ID: 36598048
    [Abstract] [Full Text] [Related]

  • 17. A multicenter phase II trial of primary prophylactic PEG-rhG-CSF in pediatric patients with solid tumors and non-Hodgkin lymphoma after chemotherapy: An interim analysis.
    Huang J, Lu S, Wang J, Jiang L, Luo X, He X, Wu Y, Wang Y, Zhu X, Chen J, Tang Y, Chen K, Tian X, Shi B, Guo L, Zhu J, Sun F, Zhen Z, Zhang Y.
    Cancer Med; 2023 Jul 23; 12(13):14130-14137. PubMed ID: 37183837
    [Abstract] [Full Text] [Related]

  • 18. Randomized controlled clinical trial of polyethylene glycol recombinant human granulocyte colony-stimulating factor in the treatment of neutropenia after chemotherapy for breast cancer.
    Huang W, Liu J, Zeng Y, Wu F, Li N, Chen K, Hong Y, Wang L, Zhen H, Lin L.
    Cancer Chemother Pharmacol; 2018 Oct 23; 82(4):607-613. PubMed ID: 30043207
    [Abstract] [Full Text] [Related]

  • 19. [Application of pegylated recombinant human granulocyte colony-stimulating factor to prevent chemotherapy-induced neutropenia in patients with lymphoma: a prospective, multicenter, open-label clinical trial].
    Huang HQ, Bai B, Gao YH, Zou DH, Zou SH, Tan H, Song YP, Li ZY, Jin J, Li W, Su H, Gong YP, Zhong MZ, Shuang YR, Zhu J, Zhang JQ, Cai Z, Teng QL, Sun WJ, Yang Y, Xia ZJ, Chen HL, Hua LM, Bao YY, Wu N.
    Zhonghua Xue Ye Xue Za Zhi; 2017 Oct 14; 38(10):825-830. PubMed ID: 29166732
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of mecapegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer: a randomized, multicenter, active-controlled phase III trial.
    Xu F, Zhang Y, Miao Z, Zeng X, Wu B, Cai L, Liu J, Wang S, Hu X, Zheng W, Chen Z, Yang Q, Jiang Z.
    Ann Transl Med; 2019 Sep 14; 7(18):482. PubMed ID: 31700918
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.